TLDR: Global healthcare commercialization company Indegene has acquired BioPharm, a specialized marketing services agency, to significantly enhance its AI-driven marketing and AdTech solutions for the global pharmaceutical industry, aiming for more precise and measurable outcomes.
Princeton, NJ / New Hope, PA / Bengaluru, KA – October 1, 2025 – Indegene, a leading global healthcare commercialization company, announced today the strategic acquisition of BioPharm, a Pennsylvania-based specialized marketing services agency previously part of Omnicom Health Group. The acquisition, executed through Indegene’s subsidiary ILSL Inc., is set to expand Indegene’s commercialization portfolio by integrating advanced AdTech capabilities that combine artificial intelligence (AI) and digital advertising.
This strategic move is designed to enable pharmaceutical companies to achieve more precise, scalable, and measurable outcomes in their marketing efforts. The integration of BioPharm’s expertise is expected to solidify Indegene’s position as a category leader in data-driven omnichannel and media solutions within the life sciences sector.
Founded in 2005, BioPharm has established itself with an impressive client roster, including 17 of the world’s top 25 biopharma organizations. The agency brings deep expertise in omnichannel strategy, comprehensive media journey management—encompassing strategy, planning, operations, and data-driven campaign execution—and a blend of analytics, automation, and targeted engagement to deliver turnkey precision marketing solutions.
Manish Gupta, Chairman and CEO of Indegene, commented on the acquisition, stating, “BioPharm has built an impressive growth flywheel, with advanced tech capabilities, deep therapeutic expertise, and long-standing client relationships. This acquisition reinforces our position as the preferred tech-native, commercialization partner for the life sciences industry, helping clients unlock greater strategic value from their marketing and AdTech investments.” He added, “I am delighted to welcome Steve and the BioPharm team to the Indegene family, and we look forward to shaping the future of AI-led commercialization together.”
Steve Carickhoff, President of BioPharm, expressed enthusiasm about joining Indegene: “Indegene is a natural home for us, given their client-focused, innovation-first, employee-centric culture—backed by strong technology platforms, data and analytics capabilities, deep medical expertise, marquee client base, and a global delivery model. We are very excited to join the larger Indegene family at a pivotal time for the industry.” Carickhoff further highlighted that Indegene’s life sciences-contextualized approach to AI would open new possibilities for delivering more personalized, measurable, and patient-focused outcomes.
The acquisition comes at a crucial time for the healthcare industry, which is navigating evolving regulatory requirements, shifting preferences of healthcare professionals, and the increasing importance of digital engagement. As pharmaceutical companies manage diverse product portfolios and prepare for new launches, there is a growing demand for specialized providers like Indegene to co-innovate AI-first, data-driven commercialization models.
Also Read:
- QInscribe Launches AI-Powered Medical Writing Service, Dramatically Accelerating Clinical Study Report Generation
- Saama Unveils Advanced Modular AI Agents to Revolutionize Clinical Development
The powerful combination of Indegene and BioPharm is expected to bring together vast, rich data assets, which will drive significantly higher Media Return on Investment (ROI) and enable more effective Agentic Operations. Seyfarth Shaw LLP represented Indegene in this transaction.
